
    
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, cross-over study.

      Patients are randomized to receive recombinant human insulin-like growth factor I (IGF-I) or
      placebo subcutaneously twice daily for 4 weeks. After a 2 week washout period, patients are
      crossed over to the other regimen for an additional 4 weeks.

      Completion date provided represents the completion date of the grant per OOPD records
    
  